NanoViricides, Inc. (NYSE American: NNVC) announced continued advancement of its broad-spectrum antiviral candidate NV-387 toward Phase II clinical development for MPox in the Democratic Republic of Congo, where regulatory approval for the trial has already been obtained. The company also outlined progress in its orphan-first regulatory strategy, including FDA orphan drug designation for measles granted subsequent to the quarter and additional applications targeting MPox and smallpox.
The company filed its quarterly report for the period ended March 31, 2026, highlighting these developments. NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is designed as a broad-spectrum antiviral for RSV, COVID-19, Long COVID, Influenza, other respiratory viral infections, MPox/Smallpox, and Measles. The company's novel nanoviricide class of drug candidates is based on intellectual property and technology from TheraCour Pharma, Inc.
For business leaders and investors, the significance lies in NanoViricides' strategy to target multiple high-impact viral diseases with a single platform. The orphan drug designation for measles, along with applications for MPox and smallpox, could provide market exclusivity and development incentives. The regulatory approval for a Phase II MPox trial in the DRC positions the company to address a pressing global health concern, potentially opening avenues for public health partnerships and funding.
NanoViricides also highlighted its other drug candidate, NV-HHV-1, for the treatment of Shingles. The company is developing drugs against a range of viral diseases including oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. The company holds a worldwide exclusive perpetual license to the TheraCour nanomedicine technology for several drugs with specific targeting mechanisms for human viral diseases.
The company's business model is based on licensing technology from TheraCour Pharma for specific application verticals. However, as with any drug development, the path is lengthy and requires substantial capital. NanoViricides stated that there can be no assurance that any of its pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development or lead to successful clinical trials or a commercial product.
The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC. The full press release can be accessed at https://ibn.fm/osO0q.
